Sanofi Reports Phase 3 PEGASUS Trial Results for Rilzabrutinib in Pemphigus Vulgaris

Sanofi today announced results from the Phase 3 PEGASUS trial evaluating rilzabrutinib in patients with moderate-to-severe pemphigus vulgaris (PV). The trial met its primary endpoint, demonstrating a significantly higher rate of complete remission off therapy compared to placebo at week 52.